TABLE 1.
Druga | Ki for 5-HT2Ab | Ki for 5-HT2Cb | DD ED50c | Potency Relative to LSD (Rat DD) | Human Dosed | Potency Relative to LSD (Human) |
---|---|---|---|---|---|---|
nM | μM/kg | mg | ||||
EthLAD | — | — | 0.02 | 185 | 0.04–0.15 | 140 |
AllyLAD | — | — | 0.013 | 285 | 0.08–0.16 | 110 |
LSD | 2–4 | 3–6 | 0.037 | 100 | 0.06–0.20 | 100 |
ProLAD | — | — | 0.037 | 100 | 0.10–0.20 | 90 |
DOB | 0.6 | 1.3 | 1.06 | 2.3 | 1–3 | 7 |
DOI | 0.7 | 2.4 | 0.28 | 9.2 | 1.5–3 | 6 |
DOM | 19 | ND | 0.89 | 3.3 | 3–10 | 2 |
Psilocin | 15–25 | 10 | 1.0 | 2.6 | 10–15 | 1 |
DMCPA | ND | ND | 0.66 | 4.5 | 15–20 | 0.7 |
MEM | 73 | 124 | 12 | 0.2 | 20–50 | 0.4 |
MMDA-2 | ND | ND | 7 | 0.4 | 25–50 | 0.4 |
Mescaline | 550 | 300 | 34 | 0.08 | 200–400 | 0.04 |
AllyLAD, N-allyl-N(6)-norLSD; DD, drug discrimination; DMCPA, (±)-trans-2,5-dimethoxy-4-methylphenylcyclopropylamine; EthLAD, N-ethyl-N(6)-norLSD; MEM, (±)-2,5-dimethoxy-4-ethoxyamphetamine; MMDA-2, (±)-2-methoxy-4,5-methylenedioxyamphetamine; ProLAD, N-n-propyl-N(6)-norLSD.
Drug abbreviations are from Shulgin and Shulgin (1991, 1997).
Affinity of phenethylamines in cloned receptors taken from Nelson et al. (1999); mescaline affinity is from Monte et al. (1997).
Drug discrimination data from Blair et al. (2000), Hoffman and Nichols (1985), Monte et al. (1997), and Nichols et al. (1984a,b, 1986, 1991).
dAveraged dose range from Shulgin & Shulgin (1991, 1997) (LSD = 100).